Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Oct
21
Today In Oncology
Remote Expert Case Reviews Identify Opportunities to Improve Cancer Care and Reduce Costs
Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction
Experts Call for Better Quality-of-Life Reporting in Adjuvant Cancer Trials
Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma
Claudia Henschke, PhD, MD Finding Lung Cancer in Time
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo